Standard purification process changes the structure of antibodies—and then changes them back

September 25, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
Standard purification process changes the structure of antibodies—and then changes them back
Antibodies can be used as drugs to treat medical conditions such as cancer, autoimmunity and inflammatory disorders. Credit: Molekuul/iStock/Thinkstock 

Monoclonal antibodies represent one of the most important segments of international biopharma, and how they are purified is a major factor in their success. Now, A*STAR researchers have revealed an unexpected physical structure change during a standard purification process that could have major implications for antibody purification going forward.

Scientists routinely exploit a bacterial molecule called A to purify antibodies from cell culture-associated contaminants. The antibodies are usually then eluted by switching from neutral to acidic pH, which disrupts the interaction with protein A. There are mysterious deficiencies in this approach, however, which rarely delivers even 99 per cent purity. Pete Gagnon and colleagues at the A*STAR Bioprocessing Technology Institute set out to find out why. "It should yield 99.999 per cent purity in a single step," says Gagnon. "For somebody having an antibody drug injected intravenously, or manufacturers making such drugs, this is a big deal."

Some studies had suggested that acidic conditions may cause the antibody structure to partially collapse, leading to aggregation. Gagnon and his team explored this by examining how pH changes affected three commonly used therapeutic antibodies in the specific context of their interactions with protein A. Intriguingly, they found the size of the antibodies was halved during elution from protein A, indicating that they had undergone a marked change in .

Although the played a role, the team was astonished to learn that the nature of the protein A-antibody interaction is behind this structural disruption. Upon binding protein A, the antibody assumes a partially unfolded structure that renders it considerably more vulnerable to environmental changes. "Our results go far beyond interesting or surprising and well into the realm of shocking," he says. "Industry has used protein A for antibody purification for decades and assumed it did not impose any structural changes on those antibodies." These changes have direct consequences—antibodies eluted under these conditions tended to form aggregates that remained stable even when they were transferred to neutral conditions.

Antibody drugs represent a large share of the therapeutic market for major diseases such as cancer and arthritis—the three tested here have each made billions of dollars for their manufacturers—and Gagnon notes that their article has already commanded attention. Subsequent work by his team has confirmed that this effect can undermine the purity of antibody preparations and has identified process steps that could mitigate this problem. "Objectively, our study will change the way industry does antibody purification," he says.

The A*STAR-affiliated researchers contributing to this research are from the Bioprocessing Technology Institute. For more information about the team's research, please visit the Downstream Processing Group webpage.

Explore further: Magnetic nanoparticles break the capacity barrier for antibody purification

More information: "Transient conformational modification of immunoglobulin G during purification by protein A affinity chromatography." Journal of Chromatography A 1395, 136–142 (2015).

Related Stories

An antibody that can attack HIV in new ways

September 11, 2015

Proteins called broadly neutralizing antibodies (bNAbs) are a promising key to the prevention of infection by HIV, the virus that causes AIDS. bNAbs have been found in blood samples from some HIV patients whose immune systems ...

Antibody-making bacteria promise drug development

August 31, 2015

Monoclonal antibodies, proteins that bind to and destroy foreign invaders in our bodies, routinely are used as therapeutic agents to fight a wide range of maladies including breast cancer, leukemia, asthma, arthritis, psoriasis, ...

Recommended for you

How stem cells self-organize in the developing embryo

January 16, 2019

Embryonic development is a process of profound physical transformation, one that has challenged researchers for centuries. How do genes and molecules control forces and tissue stiffness to orchestrate the emergence of form ...

60 percent of coffee varieties face 'extinction risk'

January 16, 2019

Three in five species of wild coffee are at risk of extinction as a deadly mix of climate change, disease and deforestation puts the future of the world's favourite beverage in jeopardy, new research warned Wednesday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.